On August 29, 2024, GSK plc announced the European Commission's approval of its RSV vaccine, Arexvy, for adults aged 50-59 at increased risk, potentially benefiting 20 million individuals in Europe. This approval follows prior authorization for older adults and is expected to reduce severe RSV-related health issues during the upcoming season.